As disclosures of life science industry payments to healthcare professionals continue with rollouts such as the Centers for Medicare and Medicaid Services’ Open Payments Database in late September, Thought Leader Select’s Paul Meade has been a sought-after expert on the impact of these disclosures on industry collaborations with key opinion leaders in medicine.
Meade, the company’s founder and president, spent 25 years leading brand and strategy teams at global drug manufacturers Merck and GlaxoSmithKline and understands the critical importance that key opinion leader interactions bring to the table in both medical affairs and commercialization efforts for pharmaceutical, biotechnology, and medical device companies.
In the attached FDA News story (subscription required), Meade provided context for greater understanding on the recently-released CMS database numbers totaling some $3.5 billion in payments to physicians. He encouraged the media and public to dig deeper in order see how honoraria and especially travel and meal costs can quickly add up as companies engage leading physicians on a broad range of scientific activities that drive product development and peer awareness that ultimately improve patient outcomes and quality of life measures over time.
For more information or media inquiries, please contact Brian Castle, Director of Global Marketing and Client Relations at Thought Leader Select, at 919-360-9690 or bcastle@thoughtleaderselect.com.
